Although multiple experimental mAbs have shown evidence of target specificity, characterised by increased serum CSF-1 and reductions in M2-associated CD163+, CD206+, and CSF-1R+ TAMs, insufficient anti-tumour activity has been displayed [68, 69]. The gene discussed is CSF1R; the disease is neoplasm.